Today I am looking at the share price prospects of three recent rockets.
A pricey pick?
Precious metals play Fresnillo (LSE: FRES) punched impressive gains on a week-on-week basis, although the business had a huge gold price bump on Friday to thank for the advance.
Indeed, the yellow metal had struggled for much of the week, even sinking to its cheapest since February at one point at $1,212 per ounce. However, poor US employment data on Friday sent investors packing back into the safe-haven asset with a vengeance.
But chatter continues to do the rounds that the Federal Reserve remains poised to hike interest rates in the coming months. And this could have significant ramifications for the precious metals suite as the dollar would gain ground, naturally.
Furthermore, with concerns over silver demand also continuing to reverberate, I reckon Fresnillo's earnings outlook could continue to toil.
And with the business dealing on a forward P/E rating of 55.5 times, I believe the digger is a risk too far at current prices.
The right medicine
Pharma play Indivior(LSE: INDV) also enjoyed monster gains in end-of-week trade following blockbuster patent news.
Indivior announced that the US District Court of Delaware had ruled that one of three patents on its Suboxone Film treatment had been contravened. Consequently Indivior cheered the that "the threat of early generic film entry has receded significantly" -- the patent in question holds up until 2024.
Subsequent heavy profit-taking has kicked in on Monday, although this currently leaves Indivior dealing on a prospective P/E rating of 13.6 times.
And although the company is expected to keep generating losses until 2017 at the earliest, I believe the drugs darling's excellent product pipeline makes it a terrific value pick for long-term investors. Indeed, Phase III results for Invidior's Buprenorphine heroine battler due later this quarter could provide Indivior's share price with fresh fuel.
Clothing giant Supergroup (LSE: SGP) also gained ground last week, the designer continuing the heady rise that kicked off in May.
Supergroup's share price has detonated 23% since the beginning of last month, investors becoming understandably giddy over the firm's recent financials. The firm saw total revenues leap 29.9% in the year to April 2016, it advised in May, a result that should propel underlying pre-tax profit to £72.5m-£74m from £63.2m in 2015, it believes.
At face value, Supergroup may appear a tad expensive for growth investors, with a forward P/E rating of 18.9 times sailing above the FTSE 100 average of 15 times.
But such a premium is fully merited, in my opinion. Supergroup's 'urban chic' lines continue to fly off the shelves across the globe, and with the business still expanding in Europe -- not to mention opening up shop in China and bolstering its position in North America -- I expect the multiple to topple in the years ahead.
But Supergroup isn't the only brilliant growth stocks currently available to savvy investors.
With this in mind, I strongly recommend you check out this special Fool report that could help you become a market millionaire!
Indeed, The Motley Fool's 10 Steps To Making A Million In The Market report highlights a number of beaten-down bargains that could be set to deliver ten-fold returns.
Click here to enjoy this exclusive 'wealth report.'It's 100% free and comes with no obligation.
Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended Supergroup. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.